A Review on Thiazolidinediones and Bladder Cancer in Human Studies
Author:
Publisher
Informa UK Limited
Subject
Cancer Research,Health, Toxicology and Mutagenesis
Link
http://www.tandfonline.com/doi/pdf/10.1080/10590501.2014.877645
Reference115 articles.
1. Peroxisome Proliferator-Activated Receptor Agonists and Bladder Cancer: Lessons from Animal Studies
2. Pioglitazone and bladder cancer in human studies: Is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?
3. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
4. Antitumor effects of energy restriction-mimetic agents: thiazolidinediones
5. The PPARγ agonist pioglitazone crosses the blood–brain barrier and reduces tumor growth in a human xenograft model
Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan;Cancers;2023-08-26
2. Cannabidiol goes nuclear: The role of PPARγ;Phytomedicine;2023-06
3. Rosiglitazone Does Not Affect the Risk of Inflammatory Bowel Disease: A Retrospective Cohort Study in Taiwanese Type 2 Diabetes Patients;Pharmaceuticals;2023-05-01
4. SGLT-2 Inhibitors in Cancer Treatment—Mechanisms of Action and Emerging New Perspectives;Cancers;2022-11-25
5. A comprehensive review on the antidiabetic attributes of thiazolidine‐4‐ones: Synthetic strategies and structure–activity relationships;Archiv der Pharmazie;2022-11-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3